JP2006249068A - Agent for preventing or treating obesity and/or diabetes containing chick-pea extract and food and drink - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an agent for preventing or treating obesity and/or type II diabetes, and to provide food and drink having an effect of preventing or improving the obesity and/or the type II diabetes. <P>SOLUTION: This agent for preventing or treating the obesity and/or the type II diabetes contains an extract extracted from chick-peas by using a polar solvent. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a preventive or therapeutic agent for obesity and / or type II diabetes containing a chickpea extract and a food or drink containing the chickpea extract.

  Plant extracts play an important role in drug development. In Western countries, at least one kind of plant extract or plant-derived compound is contained in about 25% of pharmaceutical preparations of pharmaceuticals or quasi drugs. In the United States, plant extracts account for over 95% of the crude drug market. In Germany, crude drugs made mainly from plant extracts account for about 10% of the national drug market sales and about 30% of the national OTC market. Therefore, the extract of a medicinal plant can serve as an application base of a new medicine or quasi-drug, and there is still a large market for chemicals based on a plant extract (see Non-Patent Documents 1 and 2). In China, Chinese herbal extracts have been actively developed. Although development in China is not enough, many research institutions and pharmaceutical companies have already developed hundreds of kinds of plants such as barley, kudzu and hawthorn or extracts of herbal medicines containing these plants. Yes. For example, an active ingredient (eg, flavonoid) of ginkgo is used as an extract to concentrate the active ingredient contained in the extract to about 50 times the active ingredient contained in the raw material ginkgo itself. I was able to. Therefore, the drug effect could be greatly enhanced by using the concentrated extract.

  In addition, research on soybeans is also active, and more than 300 types of functional foods using soy isoflavones are currently on the market in the United States, with annual sales reaching about 2 billion US dollars (about 210 billion yen). In Europe, Japan, South Korea, etc., health foods made mainly from soy isoflavones are well-sold, and about 10 or more types of health foods contain soy isoflavones. According to statistics, the annual demand for soy isoflavones in the international market is estimated to reach about 1500 tons in the near future, but the actual annual production is only about 300 tons. Therefore, the development of a substitute for soybean isoflavone is desired.

  The shape of a chickpea [Nuhut, ritsuinu, cico arietinum pickape] is similar to a hawk's head, and its name is called a hawk pea because its ovule sticks out in the shape of a beak. It was. Chickpeas are legumes and their origin is distributed in warm and dry areas in the western and middle eastern regions of Asia. In India it is considered the first edible legume. Chickpeas have already been cultivated in Xinjiang, China for about 2500 years, and are listed in the “Xinjiang Uyghur Drug Journal” as Uighur medicine (see Non-Patent Document 3). Chickpeas are rich in nutrients, and chickpeas contain about 14.9-24.6% by weight of protein and about 6.4% of fat, and most of the fat is unsaturated fatty acids that are good for the body. is there. For example, the fat in Kabul chickpeas contains about 50.3% by weight oleic acid and about 40% by weight oleic acid. Furthermore, the content of amino acids in chickpeas is about three times that in oats, and all eight types of amino acids necessary for the human body are contained in chickpeas. The content of oleic acid in chickpeas is about 20% higher than that in soybeans, and the content of trace elements such as iron, zinc, calcium and phosphorus in chickpeas is also higher than that of other beans. These chickpeas or chickpea seed coats work to lower neutral fat and cholesterol, and are known to be effective in controlling the central nervous system “strain” and protecting the circulatory system in the middle-aged (See Non-Patent Documents 4 and 5).

In China's Uyghur Autonomous Region, chickpeas are often used as a Uyghur medicine to treat everyday diseases. In particular, chickpeas have a clear therapeutic effect on diabetes, cardiovascular disease, kidney disease and the like. Chickpeas are also an excellent nutritional food. According to a survey by Xinjiang, there are about 600 types of Uyghur medicines in all regions, of which about 360 are used as regular medicines. Among them, about 160 kinds of local resources are used, which is about 27% of the whole Uyghur medicine. Of the common Uyghur medicines, there are about 30 types of resources dedicated to local ethnic groups, including chickpeas. In the ancient literatures “Junkang Masayori”, “Honcho Seimei”, “Sakuraku Hokusa”, etc., it is described that chickpeas have the effect of promoting the secretion of saliva and lowering neutral fat.
In the 1960s and 1970s, there is already a document describing that chickpeas have the effect of lowering neutral fat and cholesterol based on the results of experiments using laboratory mice and rabbits (Non-Patent Documents 6 to 10).
However, the effect of the chickpeas is to eat the chickpeas as they are, and there is no mention of the effect relating to the extract of chickpeas extracted using a polar solvent.
Ho Jianguo, Aika Hayashi, Akari. Pharmaceutical report, 2001, 11 (20): 719-720. Lily, Lino, Shenyang. Chinese Pharmacopoeia, 2004, 15 (9): 570-572 Chinese Pharmacy (1998 edition) Uyghur Drugs 114 pages Xiao Katsurai, Kiso Ra. , Chinese ethnographic magazine, 2003, 11 (3): 20 Letter P., The British Journal of Nutrition, 2002, Vol. 88, S239-242 Zulet MA and one other, Plant Foods Hum Nutr., 1995, Vol. 48, No. 3, p. 269-277 Mand JK et al., Indian Heart J. 1991, 43, 5, p. 347-350 Turner RC et al., United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ. ], March 14, 1998, volume 316, p. 823-828 Laakso M, et al., Circulation, 1993, 88, p. 1421-1430 McGarry JD., Diabetes, 2002, 51, p. 7-18

  An object of the present invention is to provide a preventive or therapeutic agent for obesity and / or type II diabetes and a food or drink having an effect of preventing or improving obesity and / or type II diabetes.

  The present inventors made an obese experimental animal close to human obesity by ingesting an unlimited amount of high-fat diet, and conducted various studies using this animal. As a result, the extract extracted from chickpeas using a polar solvent has an effect of lowering the weight of an increased mouse by ingesting a high-fat diet for a long time. Furthermore, serum LDL-cholesterol (low-density lipoprotein cholesterol) ) And TG (triglyceride) are also clearly decreased, and the effect of increasing HDL-cholesterol (high density lipoprotein cholesterol) is improved, lipid sedimentation in skeletal muscle tissue is improved, glycogen increases and intravascular It has been found that the film thickness can be improved. Furthermore, molecular biological studies have found that chickpeas have the effect of increasing the expression of adiponectin (Adiponectin) mRNA in the adipose tissue of mice that have been fed a high fat diet for a long time. Furthermore, the present inventors also found that an extract extracted from chickpeas using a polar solvent has an effect of lowering the blood sugar level that rises due to long-term intake of a high-fat diet. Furthermore, the present inventors have found that among polar solvents that are extraction solvents, an extract of a lower alcohol or a mixture of lower alcohol and water, and an ethanol extract thereof have unexpected and remarkable effects. . Based on these findings, the present inventors have made further studies and completed the present invention.

That is, the present invention
[1] A prophylactic or therapeutic agent for obesity and / or type II diabetes, comprising an extract obtained by extracting chickpeas with a polar solvent,
[2] The prophylactic or therapeutic agent according to the above [1], wherein obesity and / or type II diabetes is caused by decreased adiponectin secretion,
[3] The preventive or therapeutic agent according to [1] or [2] above, wherein obesity is visceral fat accumulation type obesity,
[4] The preventive or therapeutic agent according to [1] or [2] above, wherein the type II diabetes is insulin resistant type II diabetes,
[5] The agent for preventing or treating obesity and / or type II diabetes according to [1] above, wherein the extract is obtained by the following steps;
(A) crushing chickpeas;
(B) extracting the crushed chickpeas with a polar solvent and separating the extract from the chickpea extract residue;
(C) extracting the chickpea extract residue obtained in the step (b) with a polar solvent and repeating the step of separating the extract from the chickpea extract residue a plurality of times; and (d) collecting the extract and collecting the polar solvent Removing the step,
[6] The preventive or therapeutic agent according to [1] or [5] above, wherein the polar solvent is water or / and a lower alcohol,
[7] The preventive or therapeutic agent according to [1] or [5] above, wherein the polar solvent is ethanol or an aqueous ethanol solution,

[8] It contains an extract obtained by extracting chickpeas with a polar solvent, and has an effect of preventing or improving obesity and / or type II diabetes, for the improvement of obesity and / or type II diabetes , Foods and drinks with an indication that they are used,
[9] The food and drink according to the above [8], wherein obesity and / or type II diabetes is caused by decreased adiponectin secretion,
[10] The food or drink according to [8] or [9] above, wherein the obesity is visceral fat accumulation type obesity,
[11] The food or drink according to [8] or [9] above, wherein the type II diabetes is insulin resistant type II diabetes,
[12] The food and drink according to [8] above, wherein the extract is obtained by the following steps;
(A) crushing chickpeas;
(B) extracting the crushed chickpeas with a polar solvent and separating the extract from the chickpea extract residue;
(C) extracting the chickpea extract residue obtained in the step (b) with a polar solvent and repeating the step of separating the extract from the chickpea extract residue a plurality of times; and (d) collecting the extract and collecting the polar solvent Removing the step,
[13] The food or drink according to [8] or [12] above, wherein the polar solvent is water or / and a lower alcohol,
[14] The food or drink according to [8] or [12] above, wherein the polar solvent is ethanol or an aqueous ethanol solution,
[15] The food or drink according to any one of the above [8] to [14], wherein the form of the food or drink is one selected from tablets, capsules, and liquid beverages,
[16] The food or drink according to [15] above, wherein the liquid beverage is produced by the following steps;
The extract obtained in 8 above is crushed in a crusher, and the extract is further crushed in the presence of a polar dilution solvent 5 to 20 times the mass of the crushed extract, and the extract is suspended in fine particles. A step of preparing a liquid, and a step of diluting the fine particle suspension obtained above with water,
[17] The food or drink according to [15] above, which is a liquid beverage produced by the following steps;
(A) Crush the chickpeas and extract with ethanol, filter and separate the extract and chickpea extract residue, repeat the process of extracting the separated chickpea extract residue with ethanol and filtering the extract multiple times Collecting the filtrate and concentrating under pressure at 40 ° C. or lower to obtain an extract;
(B) The extract obtained in (a) was crushed with a crusher, and the crushed extract was further crushed with a crusher in the presence of 5 to 20 times the amount of DMSO aqueous solution to obtain a suspension. Next, the extract in the suspension is microparticulated, and the microparticles are uniformly dispersed in a DMSO aqueous solution to prepare a microparticle suspension; and (c) the microparticle suspension obtained in (b) is water. Thinning process,
[18] The food or drink according to [15] above, which is a liquid beverage produced by the following steps;
(A) Crush the chickpeas and extract with water, separate the extract and chickpea extract residue by filtration, further centrifuge the filtrate to separate the supernatant and chickpea extract residue, filter and Extract the chickpea extract residue obtained by centrifugation with water, filter the extract, centrifuge the filtrate multiple times, collect the supernatant, concentrate under reduced pressure at 60 ° C or lower, extract Obtaining
(B) The extract obtained in (a) was crushed with a crusher, and the crushed extract was further crushed with a crusher in the presence of 5 to 20 times the amount of DMSO aqueous solution to obtain a suspension. Next, the extract in the suspension is made into fine particles, and the fine particles are uniformly dispersed in a DMSO aqueous solution to produce a fine particle suspension; and (c) the fine particle suspension obtained in (b) above is prepared. The food and drink according to any one of [8] to [18] above, wherein the food and beverage is diluted with water, and [19] a food for specified health use,
About.

The present invention also provides:
[20] A method for preventing and / or treating obesity and / or type II diabetes, comprising administering an extract extracted from chickpeas using a polar solvent to mammals including humans,
[21] A method for preventing or ameliorating obesity and / or type II diabetes, characterized by feeding a mammal including a human with a food or drink containing an extract extracted from chickpeas using a polar solvent ,
[22] Use of an extract extracted from chickpeas using a polar solvent for the manufacture of a medicament for preventing and / or treating obesity and / or type II diabetes, and [23] obesity and / or type II Use of an extract extracted from chickpeas using a polar solvent to produce a food or drink that prevents and / or ameliorates diabetes,
About.

An extract obtained by extracting chickpeas used in the present invention with a polar solvent has a preventive or therapeutic effect on obesity or type II diabetes.
The preventive or therapeutic agent of the present invention or the food or drink of the present invention can prevent or ameliorate obesity, particularly visceral fat accumulation-type obesity in which visceral fat accumulates. Visceral fat accumulation-type obesity triggers adult diseases such as hyperlipidemia, diabetes, or hypertension, so prevention or improvement of visceral fat accumulation-type obesity can lead to prevention, treatment, or improvement of adult diseases . In connection with the above, the preventive or therapeutic agent of the present invention or the food or drink of the present invention prevents or ameliorates obesity due to intake of a high fat diet, and at the same time, LDL-, which is a serum lipid such as total cholesterol, TG or bad cholesterol Since it has the effect of lowering cholesterol and the like and increasing HDL-cholesterol, which is good cholesterol, hyperlipidemia can be prevented or treated or improved. Furthermore, since the prevention of hyperlipidemia can prevent arteriosclerosis in the heart and brain due to hyperlipidemia, for example, cerebral artery disease such as cerebral infarction, coronary artery disease such as angina, myocardial infarction, etc. Can be prevented.
Moreover, the preventive or therapeutic agent of the present invention or the food or drink of the present invention has an effect of reducing blood glucose level and improving glucose tolerance against type II diabetes caused by intake of a high fat diet.
In addition, the preventive or therapeutic agent of the present invention or the food or drink of the present invention enhances the expression of the adiponectin gene in adipocytes, and thus is a kind of cytokine that is considered to have an effect on insulin sensitivity, vascular function, etc. Can promote secretion of adiponectin. For example, when the blood adiponectin concentration decreases due to visceral fat accumulation or the like, insulin resistance and coronary artery disease are induced. However, the preventive or therapeutic agent of the present invention or the food or drink of the present invention can promote the secretion of adiponectin. Therefore, it is useful for type II diabetes, particularly insulin resistance diabetes and coronary artery disease.

  The present invention relates to a prophylactic and / or therapeutic agent for obesity and / or type II diabetes, comprising an extract obtained by extracting chickpeas with a polar solvent (hereinafter also referred to as chickpea extract), and a food and drink. .

  As the chickpea used in the present invention, either a large grain type (galvanso) or a small grain type (black chana) can be preferably used as long as it is a legume pea. Chick beans may be used immediately after collection or after drying.

Examples of the polar solvent used for extraction in the present invention (hereinafter sometimes referred to as a polar solvent for extraction) include water or an organic polar solvent and a mixed solvent thereof.
The water is not particularly limited as long as it is drinkable. For example, normal water such as tap water or well water; normal water is distilled, ion exchange, ultrafiltration (reverse osmosis method / ultrafiltration), or these Purified water treated by a combination of the above; natural water such as ground water or brine; water for injection; sterilized water or alkaline ionized water. Of these, purified water is preferred, and deionized water treated with both a cation exchange resin and an anion exchange resin is particularly preferred.

Examples of the organic polar solvent include acetone, methyl ethyl ketone, tetrahydrofuran, dioxane, acetonitrile, lower alcohol, N, N-dimethylacetamide, dimethylformamide, N-methylpyrrolidone (NMP), ethylene glycol, dimethyl sulfoxide (DMSO), trichloroethylene, acetonitrile. Etc. Examples of the lower alcohol include alcohols having 1 to 4 carbon atoms (eg, methanol, ethanol, isopropanol, propanol, butanol, etc.).
Considering the efficacy of chickpea extract and finally being able to be incorporated into foods and drinks, the polar solvent is more preferably water, lower alcohol or DMSO from the viewpoint of safety.

The mixed solvent is preferably a mixed solvent of water and an organic polar solvent, and examples thereof include lower alcohol aqueous solutions of lower alcohol and water (eg, methanol aqueous solution, ethanol aqueous solution, isopropanol aqueous solution, propanol aqueous solution, butanol aqueous solution, etc.). The concentration of the organic polar solvent in the mixed solvent of water and the organic polar solvent is about 0.1 to 99.5% (V / V), preferably about 30 to 99.5% (V / V), more preferably Is about 50-99.5% (V / V).
The preferred polar solvent in the present invention is water, a lower alcohol or a lower alcohol aqueous solution, more preferably a lower alcohol or a lower alcohol aqueous solution, particularly preferably ethanol or an ethanol aqueous solution. The lower alcohol aqueous solution naturally includes water-containing lower alcohols such as water-containing ethanol [water content 5% (V / V) or less].

The extraction method using a polar solvent for chickpeas used as a raw material in the present invention is not particularly limited, and is performed by bringing a polar solvent into contact with the chickpeas. The chickpeas can be used as they are or, for example, those obtained by crushing, crushing, cutting or chopping chickpeas. Among them, chickpeas excellent in extraction efficiency, for example, ground to about 1 to 5 mm square, are preferable. For the pulverization, known pulverization means can be used. For example, it is preferable to pulverize with a pulverizer such as a mill.
Extraction can be carried out by immersing, for example, pulverized chickpeas in a polar solvent and, for example, a known method such as ultrasonic irradiation, heating reflux, cooling or digestion, or a combination of these methods. Among them, the method using ultrasonic irradiation with good extraction efficiency is preferable. Extraction may be performed at room temperature or under heating. Although extraction temperature is not specifically limited, It is preferable that it is below the boiling point of a solvent. The time required for extraction depends on the temperature condition and the extraction method. For example, when extraction is performed by ultrasonic irradiation, the irradiation time (extraction time) is usually about 0.5 to 5 hours, preferably about 2 to 3 hours. Degree.

Next, the extracted chickpea soaked solution is a known method such as filtration using paper, cloth (eg, gauze), glass filter or membrane filter, centrifugation, or juice extraction, or a combination of these known methods. It is preferable to separate the extract from the chickpea extract residue (hereinafter sometimes simply referred to as the extract residue).
It is preferable to apply the above extraction method with a polar solvent usually about 1 to 10 times, preferably about 2 to 5 times, using the above-described extraction residue instead of chickpeas. Repeat the extraction and combine the extracts. In this way, the components in chickpeas can be extracted sufficiently.

  The polar solvent contained in the obtained extract can be removed by a known means. The removal of the polar solvent can be carried out by concentrating the extract under normal pressure, pressure or reduced pressure. Among these, it is preferable to perform concentration under pressure or reduced pressure. Concentration may be performed at room temperature or under heating. Among these, it is preferable to carry out under heating. The heating temperature is not particularly limited, but is preferably not higher than the boiling point of the solvent, more preferably about 30 to 70 ° C. Further, the obtained extract may be lyophilized as it is or after concentration by any of the above means.

  The preventive or therapeutic agent of the present invention can be produced and used as a medicine by blending chickpea extract as an active ingredient. When used as a medicine, the chickpea extract may be administered as it is, but in general, it is desirable to administer it in the form of a pharmaceutical composition containing the chickpea extract and a pharmaceutical additive. The pharmaceutical composition may take the form of oral solid preparations such as capsules, tablets (including coated tablets such as sugar-coated tablets or enteric tablets or multilayer tablets), powders or granules, or oral liquid preparations. It may take the form of parenteral preparations such as injections, infusions, and suppositories. These preparations can be produced according to known methods.

  Examples of pharmaceutical additives that are usually used in solid preparations such as capsules, tablets, powders or granules include excipients (eg, lactose, sucrose, glucose, starch, crystalline cellulose, etc.), binders ( Examples: starch paste solution, hydroxypropylcellulose solution, carmellose solution, gum arabic solution, gelatin solution, sodium alginate solution, etc.), disintegrant (eg starch, carmellose sodium, calcium carbonate, etc.), lubricant (eg stearin) Magnesium oxide, talc, stearic acid, calcium stearate, etc.), surfactant (eg, polysorbate 80, polyoxyethylene hydrogenated castor oil, etc.), thickener (eg, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, polyethylene glycol, etc.) ) Etc. , But it is not limited to these. Tablets or granules are coated with a coating agent (eg gelatin, white sugar, gum arabic, carnauba wax, cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, etc.). May be. The capsule may be a hard capsule, a microcapsule, a soft capsule, or the like. The solid preparation can be produced by a known method.

  Liquid formulations suitable for oral administration can be prepared by dissolving or suspending chickpea extract in a solvent or dispersion medium, for example, a polar diluent solvent. As the polar dilution solvent, for example, water, ethanol, DMSO, ethanol aqueous solution, DMSO aqueous solution and the like that do not adversely affect the human body are particularly preferable. Water, an aqueous ethanol solution or an aqueous DMSO solution is preferred. The concentration of the aqueous ethanol solution or DMSO aqueous solution is usually about 0.01 to 50% (V / V), preferably about 0.01 to 20% (V / V), more preferably about 0.05 to 10% (V / V), particularly preferably about 0.1 to 1% (V / V).

More specifically, the liquid preparation can be produced by the following steps.
(A) Chick bean extract is put into a crusher (eg, mortar, mill, etc.) and crushed, and a polar diluent solvent, for example, about 0.05 to 0.2% (V / V) DMSO aqueous solution is added to chickpeas. The suspension is preferably further crushed into a suspension while gradually adding about 5 to 20 times the mass of the extract, preferably about 8 to 12 times the mass.
(B) Next, the suspension obtained in (a) is further microparticulated with chickpea extract, for example, by ultrasonic irradiation or a homogenizer, and the chickpea extract is uniformly dispersed in a polar diluent solvent; It is preferable to do this. The fine particle suspension preferably contains chickpea extract at a dilution of about 5 to 20 times, preferably about 8 to 12 times.
(C) The fine particle suspension obtained in (b) above is diluted with water (eg, distilled water, purified water, etc.) at the time of taking, and the content of chickpea extract is usually about 0.1 to 2 mass. %, Preferably about 0.2 to 1% by mass, more preferably about 0.4 to 0.8% by mass.

  Liquid formulations include, for example, sugars (eg, sucrose, sorbit, fructose, etc.), glycols (eg, polyethylene glycol, propylene glycol, etc.), dispersing or thickening agents (eg, gelatin, gum arabic, hydroxyethyl cellulose, hydroxy Propyl cellulose, polyvinyl alcohol, polyethylene glycol, etc.), emulsifier (eg, glycerin fatty acid ester, sucrose fatty acid ester, etc.), solubilizer (eg, gum arabic, polysorbate 80, etc.), pH adjuster (eg, citric acid, citric acid, etc.) Acid trisodium, etc.) and preservatives (eg, paraoxybenzoates, etc.) may be incorporated.

  Among preparations suitable for parenteral administration, preparations for intravascular administration such as injections and infusions can be prepared preferably using an aqueous medium isotonic with body fluids. For example, the injection is prepared as a solution, suspension or dispersion together with an appropriate auxiliary agent using an aqueous medium selected from distilled water for injection, salt solution, glucose solution or a mixture of salt solution and glucose solution, according to a conventional method. can do. Suppositories for enteral administration can be prepared using carriers such as cacao butter, hydrogenated fat or hydrogenated carboxylic acid.

  Moreover, the food / beverage products of this invention can be used as food / beverage products which have an obesity and / or type II diabetes effect by mix | blending a chickpea extract. The food and drink of the present invention may be a chickpea extract as it is, but generally it is preferably in the form of a food composition containing a chickpea extract and an additive used as a normal food ingredient. The food composition may take the form of a solid composition such as a capsule, a tablet (including a coated tablet such as a sugar-coated tablet or a multilayer tablet, or a mouth disintegrating agent), a powder or a granule. The liquid composition may be in the form of a liquid composition. Examples of the additive include excipients (eg, lactose, dextrin, corn starch, crystalline cellulose, etc.), lubricants (eg, magnesium stearate, sucrose fatty acid ester, glycerin fatty acid ester, etc.), disintegrants (eg, Carboxymethylcellulose calcium, anhydrous calcium hydrogen phosphate, calcium carbonate, etc.), binders (eg, starch paste solution, hydroxypropylcellulose solution, gum arabic solution, etc.), solubilizers (eg, gum arabic, polysorbate 80, etc.), Sweeteners (eg, sugar, fructose, glucose liquid sugar, honey, aspartame, etc.), coloring agents (eg, β-carotene, edible tar dye, riboflavin, etc.), preservatives (eg, sorbic acid, methyl paraoxybenzoate, sulfite) Sodium), thickeners (eg sodium alginate, cal Sodium xymethylcellulose, sodium polyacrylate, etc.), antioxidant (eg, dibutylhydroxytoluene, butylhydroxyanisole, ascorbic acid, tocopherol, etc.), flavor (eg, peppermint, strawberry flavor, etc.), acidulant (eg, citric acid) , Lactose, DL-malic acid, etc.), seasonings (eg, DL-alanine, 5′-sodium inosinate, sodium L-glutamate, etc.), emulsifiers (eg, glycerin fatty acid ester, sucrose fatty acid ester, etc.), pH adjustment Agents (eg, citric acid, trisodium citrate, etc.), vitamins, minerals, amino acids, pigments and the like. The solid composition can be produced according to a conventional method. Moreover, a liquid composition can be manufactured similarly to the liquid formulation suitable for the said oral administration.

  Moreover, the food / beverage products of this invention can be manufactured by mix | blending a chickpea extract or the solid composition or liquid composition containing it with food / beverage products. Examples of such foods and beverages include confectionery (eg, gum, candy, caramel, chocolate, cookies, snack confectionery, jelly, gummy, tablet confectionery, etc.), noodles (eg, soba, udon, ramen, etc.), and dairy products. (Eg, milk, ice cream, yogurt, etc.), seasonings (eg, miso, soy sauce, etc.), soups, beverages (eg, juice, coffee, tea, tea, carbonated drinks, sports drinks, etc.) Examples include foods and dietary supplements (eg, energy drinks).

Since the food / beverage products of this invention contain the chickpea extract which has an obesity and / or type II diabetes effect, the indication that it is used for obesity and / or type II diabetes improvement is displayed on the packaging of food / beverage products, etc. It is preferable to attach to.
Moreover, the food / beverage products of the present invention can be a food for specified health use used to improve obesity and / or type II diabetes.

  About 10-95 mass% is normally preferable, and, as for the compounding quantity of the chickpea extract to the said pharmaceutical composition or food composition, about 50-90 mass% is more preferable.

The preventive or therapeutic agent of the present invention can be used for the prevention or treatment of obesity, particularly visceral fat accumulation-type obesity, and the food and drink of the present invention can be used for suppression, improvement, etc. of obesity, particularly visceral fat accumulation-type obesity.
The preventive or therapeutic agent of the present invention can be used for the prevention or treatment of type II diabetes, particularly insulin resistance type II diabetes. Moreover, the food / beverage products of this invention can suppress the onset of type II diabetes, especially insulin resistant type II diabetes, and can be used for improving the pathological condition of the diabetes. Furthermore, the preventive or therapeutic agent of the present invention is used for various diseases associated with obesity or type II diabetes, such as hyperlipidemia, hypertension or arteriosclerosis (eg, cerebral artery disease such as cerebral infarction, angina pectoris, It can be used for prevention or treatment of coronary artery disease such as myocardial infarction. Moreover, the food / beverage products of this invention can suppress the onset of the various diseases accompanying the above-mentioned obesity or type II diabetes, and can be used for improving the pathological conditions of the diseases.

  The administration or intake of the chickpea extract used in the present invention varies depending on the degree of obesity or symptoms of type II diabetes, the subject of administration, the administration method, etc. For example, when administered orally to adults, several times a day A single dose is about 100 to 1000 mg, preferably about 200 to 800 mg.

  Hereinafter, the present invention will be described more specifically based on examples, but the present invention is not limited thereto.

[Materials and methods]
1. Extraction method of chickpea extract (1) Extraction with ethanol The chickpeas are crushed to a size of 1 to 5 mm square and placed in a beaker, and 3 to 4 parts by mass of ethanol is added to the chickpeas for 2 hours. Was irradiated. After ultrasonic irradiation, the mixture of chickpeas and ethanol was filtered with a filter paper, and the filtrate was separated. Ethanol (2 to 3 parts by mass with respect to chickpeas) was added to the residue, and ultrasonic irradiation and filtration were similarly performed 4 to 5 times. The filtrate was collected and concentrated under pressure at a temperature of 40 ° C. or lower to obtain a chickpea extract with ethanol, which was used as a chickpea ethanol extract.
(2) Extraction with water The chickpeas were crushed to a size of 1 to 5 mm square and placed in a beaker, and 3 to 4 parts by mass of deionized water was added to the chickpeas and irradiated with ultrasonic waves for 3 hours. After ultrasonic irradiation, the mixture of chickpeas and deionized water was filtered with gauze, and the filtrate was separated. The filtrate was further centrifuged to separate the supernatant. Deionized water (2 to 3 parts by mass with respect to chickpeas) was added to the residue, and ultrasonic irradiation, filtration and centrifugation were performed three times in the same manner. The supernatant was collected and concentrated under reduced pressure at a temperature of 60 ° C. or lower to obtain an extract of chickpeas with water to obtain a chickpea water extract.
(3) Chickpea ethanol extract beverage and chickpea water extract beverage 4 g of the extract obtained in (1) or 8 g of the extract obtained in (2) was put into a mortar and finely crushed, and 0.1% ( (V / V) 100 mL of DMSO aqueous solution was gradually poured while being poured. The ground extract was further uniformly dispersed by ultrasonic irradiation, and then a suspension was prepared by diluting the extract 10 times. The suspension was further diluted with distilled water before ingesting the animals to prepare a chickpea ethanol extract beverage and a chickpea water extract beverage. Each extract contained in the beverage was prepared so that the chickpea ethanol extract was 4 g / L and the chickpea water extract was 8 g / L.

2. Experimental animals Mice with a body weight of about 40 g were divided into the following 5 groups.
(A) Normal feed diet group (hereinafter abbreviated as normal group)
(B) High fat diet group (hereinafter abbreviated as high fat group)
(C) High fat + chickpea flour mixed feed diet group (hereinafter abbreviated as chickpea administration group)
(D) High-fat feed diet + chick pea water extract beverage (0.4 g / kg mouse / day as chick pea water extract dry mass) Food and drink group (hereinafter abbreviated as chick pea water extract administration group)
(E) High fat feed diet + chick bean ethanol extract beverage (0.2 g / kg mouse / day as dry mass of chick bean ethanol extract) Food and drink group (hereinafter abbreviated as chick bean ethanol extract administration group)

3. Feed component (a) As a normal feed, a basic feed (60% by weight of carbohydrate, 22% by weight of protein, 10% by weight of fat, and 8% by weight of other) was used.
(B) The high-fat feed is made by adding lard, powdered milk, powdered fish, sugar, etc. to the basic feed (carbohydrate 40%, protein 13%, fat 40%, others 7%) did.
(C) The high-fat + chickpea flour mixed feed was used by reducing 10% by mass of the high-fat feed and adding the same amount of chickpea flour instead. However, the total calorie content, carbohydrate, protein, and fat ratio were adjusted to be almost the same as the feed of the high fat diet group.

4). Administration method:
During the experimental period, the above-mentioned dietary intake of the mice in each group was free feeding. In addition, sterilized water was freely ingested into the normal group, the high fat diet group, and the chickpea administration group. In the chick pea water extract administration group or the chick pea ethanol extract administration group, the chick bean water extract beverage or the chick bean ethanol extract beverage was freely ingested by the mice instead of sterilized water. The experimental period was 100 days. Body weight was measured once a month during the experimental period.

5. Insulin tolerance test (ITT)
Mice received insulin intraperitoneally at a rate of 1 International Unit (IU) / kg. Blood was collected from the tail vein of mice before and after administration, and at 0, 15, 30, 60, 90, 120, and 180 minutes, and blood glucose level was measured.
By this test, insulin resistance due to insulin receptor abnormality can be measured. Since type II diabetes usually causes an abnormality in the insulin receptor, type II diabetes can be diagnosed by measuring insulin resistance.

6). Measurement of TG, total cholesterol, LDL-cholesterol and HDL-cholesterol levels Serum was separated from blood collected by decapitation on day 100 of the experiment. Serum TG, total cholesterol, LDL-cholesterol and HDL-cholesterol were measured using a commercially available measurement kit (manufactured by Wako Pure Chemical Industries, Ltd.).

7). Oral glucose tolerance test (OGTT) and insulin release test (IRT)
A 20% by mass glucose solution was orally administered to a fasted mouse (the amount of glucose administered was 2 g / kg mouse body weight). Blood was collected from the mouse tail vein before and 120 minutes after administration of glucose, and the blood glucose level and insulin level were measured. The blood glucose level was measured using a self blood glucose level measuring device (one-touch assist; manufactured by Johnson & Johnson Co., Ltd.). Insulin levels were measured using a Linco insulin assay kit (RIA, USA).

8). Isolation of visceral fat (cold testicular adipose tissue) and expression of leptin, LPL receptor and adiponectin mRNA in the adipose tissue Visceral fat (cold testicular adipose tissue) from mice after collecting blood according to 6 above ). The separated tissue weight was measured.
Next, total mRNA was extracted from the epididymis adipose tissue separated according to the protocol attached to the TRIZOL reagent (Invitrogen). The extracted mRNA was electrophoresed on a 1% formaldehyde-denatured agarose gel. The electrophoresed gel was transferred (blotted) to a high bond-N membrane (Amersham Pharmacia Biotech). The transferred high bond-N film was hybridized with a ³² P-labeled cDNA probe using a random primed DNA probe kit (manufactured by Takara Bio Inc.). The hybridization was performed at 68 ° C. overnight. The hybridized membrane was washed with 2x SSC solution (saline-sodium citrate solution) -0.1% SDS (sodium dodecyl sulfate) at room temperature and then 0.1x SSC-0.1% SDS at 68 ° C. Washed with. The washed membrane was lightly dried, overlapped with an autoradiography film (Hyperfilm; manufactured by Amersham BioSaens Co., Ltd.) and an intensifying screen and subjected to autoradiography at -70 ° C.

[Test results]
1. Influence on mouse body weight increase The body weights of the normal group, high fat diet group, chickpea-administered group, chickpea water extract-administered group, and chickpea ethanol extract-administered group 100 days after the start of the experiment were 52.13 ± 3 g and 69. 00 ± 6.26 g, 63.78 ± 11.28 g, 62.33 ± 7.04 g and 57.11 ± 6.13 g.
The body weight of mice in the high fat diet group increased significantly compared with that in the normal group, but in the chickpea ethanol extract administration group, the increase in mouse body weight due to high fat diet was markedly suppressed [Risk rate 1 % Or less (p <0.01) with significant difference]. Moreover, although the mouse weight of the chickpea administration group and the chickpea water extract administration group was lower than that of the high fat diet group, there was no statistically significant difference (see FIGS. 1 and 2).

2. Fasting blood glucose level Fasting blood glucose levels in the normal group, the high fat diet group, the chick pea water extract administration group, and the chick pea ethanol extract administration group on the 60th day from the start of the experiment were 2.96 ± 0.6 mM and 4.01 ±, respectively. They were 0.94 mM, 3.47 ± 1.1 mM and 3.01 ± 0.55 mM (see FIG. 3).
Fasting blood glucose level in the high fat diet group was significantly increased compared to that in the normal group. This indicates that fasting blood glucose levels are increased by high fat diet. In the chickpea water extract and chickpea ethanol extract administration groups, an effect of suppressing an increase in fasting blood glucose level due to a high fat diet was observed. In particular, the effect of the chickpea ethanol extract administration group was remarkable.

3. Visceral fat (cold testicular fat tissue) weight Visceral fat (cold testicular adipose tissue) weight of normal group, high fat diet group, chickpeas administered group, chickpea water extract administered group, chickpea ethanol extract administered group 100 days after the start of the experiment Were 1.15 ± 0.37 g, 3.28 ± 0.59 g, 3.35 ± 1.34 g, 3.12 ± 0.98 g and 2.22 ± 0.62 g, respectively.
The visceral fat weight of the high fat diet group increased about 3 times compared to that of the normal group. This indicates that visceral fat is increased by high-fat diet. The visceral fat weight of the mice in the chickpea ethanol extract administration group was significantly reduced compared to the visceral fat weight of the mice in the high fat diet group (significant difference at a risk rate of 5%, p <0.05). . The visceral fat weight of the mice of the chickpea-administered group and the chickpea water extract-administered group was not statistically significant compared to the visceral fat weight of the mice of the high-fat diet group. (See Figure 4)

4). Effect on insulin resistance The insulin resistance of each group of mice 90 days after the start of the experiment was evaluated based on ITT. As a result, it was confirmed that the insulin resistance due to the long-term high-fat diet was remarkably improved in the chickpea administration group, the chickpea water extract administration group and the chickpea ethanol extract administration group. This is thought to be due to the addition of chickpea flour to the feed and the chickpea water extract beverage or chickpea ethanol extract beverage. There was no significant difference between the chickpea administration group, the chickpea water extract administration group and the chickpea ethanol extract administration group. (See Figs. 5 and 6)

5. Effects on Serum TG, Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol 100 days after the start of the experiment, mouse serum TG, total cholesterol, and LDL-cholesterol in the high fat diet group were significantly increased as compared to the normal group. In the chickpea administration group, the chickpea water extract administration group, and the chickpea ethanol extract administration group, TG, total cholesterol, and LDL-cholesterol that were elevated by high-fat diet were suppressed. In particular, in the chickpea ethanol extract administration group, the increase of TG, total cholesterol, and LDL-cholesterol due to the high-fat diet was remarkably suppressed (see Table 1). This is considered to be caused by the increase in TG, total cholesterol, and LDL-cholesterol was suppressed by the addition of chickpea powder to the feed and the chickpea water extract beverage or chickpea ethanol extract beverage. In particular, the chickpea ethanol extract beverage showed a remarkable inhibitory effect on the increase in TG, total cholesterol, and LDL-cholesterol caused by high-fat diet.
In addition, HDL-cholesterol in the high fat diet group fed the high fat diet decreased compared to that in the normal group. In the chick pea water extract administration group and the chick pea ethanol extract administration group, the decrease in HDL-cholesterol by the high-fat diet was suppressed (see FIG. 10).

(Note 1) (b) Normal group, (b) High fat diet group, (c) Chick bean administration group, (d) Chick bean water extract administration group, (e) Chick bean ethanol extract administration group (Note 2) * Indicates that there is a significant difference with respect to the (b) high fat diet group at a risk rate of 5% or less (p <0.05), and ** indicates that the risk rate is 1 for the (b) high fat diet group. % Or less (p <0.01) indicates that there is a significant difference. Δ indicates that there is a significant difference with respect to the chickpea-administered group at a risk rate of 5% or less (p <0.05).

6). Blood glucose level and insulin level in OGTT The blood glucose level and blood insulin level of mice 2 hours after glucose load were significantly higher in the chickpea ethanol extract administration group compared to the blood glucose level and blood insulin level in the high fat diet group It was low. The blood sugar level and blood insulin concentration in the chick soy extract administration group were lower than the blood sugar level and blood insulin concentration in the high fat diet group, but no significant difference was observed. The blood sugar level of the chickpea administration group did not change compared to the blood sugar level of the high fat diet group (see Table 2).

(Note 1) (b) Normal group, (b) High fat diet group, (c) Chick bean administration group, (d) Chick bean water extract administration group, (e) Chick bean ethanol extract administration group (Note 2) * * Indicates that (b) there is a significant difference with respect to the high fat diet group at a risk rate of 1% or less (p <0.01). Δ indicates that there is a significant difference with respect to the normal group at a risk rate of 5% or less (p <0.05).

7). The expression results of leptin (Leptin) mRNA, LPL receptor mRNA and adiponectin (Adiponectin) mRNA in mouse adipose tissue are shown in FIG.
(1) Leptin mRNA
It was found that the expression of leptin mRNA was significantly increased in the adipose tissue of the high fat diet group compared to the normal group. On the other hand, although the amount of leptin mRNA in the adipose tissue of the chickpea ethanol extract administration group was slightly increased compared with that of the normal group, the level was considered to be slight. This shows that leptin secretion increases in the high-fat diet, but administration of chickpea ethanol extract suppresses increase in leptin secretion due to the high-fat diet. It is known that blood leptin concentration shows a very good positive correlation with BMI (Body Mass Index) and body fat percentage in humans or body fat content in rodents. This shows that in the high fat diet group, the body fat content is increased by the high fat diet. On the other hand, in the chickpea ethanol extract administration group, it turns out that the increase in the body fat content by a high fat feed diet was suppressed.
(2) LDL receptor mRNA
It was found that the expression of LDL receptor mRNA was significantly increased in the adipose tissue of the high fat diet group compared to the normal group. On the other hand, the amount of LDL receptor in the adipose tissue of the chickpea ethanol extract administration group was about the same as that of the normal group.
(3) Adiponectin mRNA
It was found that the expression of adiponectin mRNA was decreased in the adipose tissue of the high fat diet group compared to the normal group. On the other hand, the level of adiponectin mRNA expression in the adipose tissue of the chickpea ethanol extract administration group was about the same as that of the normal group. This shows that the secretion of adiponectin is reduced by high-fat diet, but the decrease in adiponectin secretion by high-fat diet is suppressed by administration of chickpea ethanol extract.

Conclusion:
An extract (chickpea bean extract) extracted using a polar solvent (water or ethanol) suppressed weight gain due to a high-fat diet as compared to chick beans themselves (eg, chickpea flour). This indicates that chickpea extract prevents or suppresses obesity. In particular, chickpea ethanol extract has an excellent effect that the effect is greater than that of chickpea water extract even at a concentration of 1/2 of chickpea water extract, and that fat that adheres to the internal organs is remarkably suppressed by high-fat diet. showed that.
Moreover, the chickpea extract suppressed the increase in serum TG, total cholesterol, and bad cholesterol, which are called bad cholesterol, and the decrease in HDL-cholesterol, which is called good cholesterol, from the high fat diet. The effect was also greater than that of chickpea itself. This indicates that chickpea extract can be preferably used for prevention, improvement or treatment of hyperlipidemia. In particular, chickpea ethanol extract was highly effective even at a concentration half that of chickpea water extract, and was found to be particularly useful for the prevention, improvement or treatment of hyperlipidemia.
In addition, chickpea extract increases blood sugar levels due to high-fat diet, suppresses glucose tolerance in glucose tolerance tests, suppresses insulin resistance, suppresses adiponectin secretion, and increases body fat content. Suppressed. These effects indicate that chickpea extract suppresses body fat accumulation type obesity and is useful for type II diabetes, particularly insulin resistance type II diabetes. In particular, in chickpea ethanol extract, the above-mentioned effect is remarkably recognized, and chickpea ethanol extract shows that it can be a prophylactic, ameliorating or therapeutic agent for obesity and type II diabetes, particularly insulin resistance type II diabetes. .

[Formulation Example 1]
Tablets Chickpea ethanol extract 10.0
Lactose 75.0
Magnesium stearate 15.0
Total 100.0
Each said weight part is mixed uniformly, and it is set as a tablet according to a conventional method.

[Formulation Example 2]
Granules Chickpea ethanol extract 20.0
Starch 30.0
Lactose 50.0
Total 100.0
The above parts by weight are uniformly mixed and granulated according to a conventional method.

  The preventive or therapeutic agent of the present invention is useful for preventing or treating obesity and / or type II diabetes, and the food and drink of the present invention is useful as a functional food for preventing or improving obesity and / or type II diabetes. .

FIG. 1 is a graph showing changes in body weight of mice in each group over time. In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 2 is a diagram showing the body weight of each group of mice on the 90th day from the start of the experiment. In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 3 is a graph showing fasting blood glucose levels of mice in each group on the 60th day from the start of the experiment. In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 4 is a diagram showing the visceral fat (cold testicular fat) amount of each group of mice on the 100th day from the start of the experiment. In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 5 is a diagram showing blood glucose levels 180 minutes after insulin administration to mice in the insulin resistance test (ITT). In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 6 is a graph showing changes over time in blood glucose levels after insulin administration in mice of each group in the insulin resistance test (ITT). In the figure, (1) is a normal group, (2) is a high fat diet group, (3) is a chickpea administration group, (4) is a chickpea water extract administration group, (5) is a chickpea ethanol extract administration group. Show. FIG. 7 is a view showing the expression of leptin mRNA, LPL receptor mRNA or adiponectin mRNA in adipose tissue. In the figure, 1 is a normal group, 2 is a high fat diet group, and 5 is a chickpea ethanol extract administration group.

Claims (19)

  A prophylactic or therapeutic agent for obesity and / or type II diabetes, comprising an extract obtained by extracting chickpeas with a polar solvent.   2. The preventive or therapeutic agent according to claim 1, wherein obesity and / or type II diabetes is caused by a decrease in adiponectin secretion.   3. The preventive or therapeutic agent according to claim 1, wherein the obesity is visceral fat accumulation type obesity.   The preventive or therapeutic agent according to claim 1 or 2, wherein the type II diabetes is insulin resistant type II diabetes. The prophylactic or therapeutic agent according to claim 1, wherein the extract is obtained by the following steps;
(A) crushing chickpeas;
(B) extracting the crushed chickpeas with a polar solvent and separating the extract from the chickpea extract residue;
(C) extracting the chickpea extract residue obtained in the step (b) with a polar solvent and repeating the step of separating the extract from the chickpea extract residue a plurality of times; and (d) collecting the extract and collecting the polar solvent Removing.   The preventive or therapeutic agent according to claim 1 or 5, wherein the polar solvent is water or / and a lower alcohol.   6. The preventive or therapeutic agent according to claim 1, wherein the polar solvent is ethanol or an aqueous ethanol solution.   It contains an extract obtained by extracting chickpeas with a polar solvent, has an effect of preventing or improving obesity and / or type II diabetes, and is used for improving obesity and / or type II diabetes A food or drink with an indication that it is   The food and drink according to claim 8, wherein obesity and / or type II diabetes is caused by a decrease in adiponectin secretion.   The food or drink according to claim 8 or 9, wherein the obesity is visceral fat accumulation-type obesity.   The food or drink according to claim 8 or 9, wherein the type II diabetes is insulin resistant type II diabetes. The extract according to claim 8, wherein the extract is obtained by the following steps;
(A) crushing chickpeas;
(B) extracting the crushed chickpeas with a polar solvent and separating the extract from the chickpea extract residue;
(C) extracting the chickpea extract residue obtained in the step (b) with a polar solvent and repeating the step of separating the extract from the chickpea extract residue a plurality of times; and (d) collecting the extract and collecting the polar solvent Removing.   The food or drink according to claim 8 or 12, wherein the polar solvent is water or / and a lower alcohol.   The food or drink according to claim 8 or 12, wherein the polar solvent is ethanol or an aqueous ethanol solution.   The form of food / beverage products is one selected from a tablet, a capsule, and a liquid drink, Food / beverage products in any one of Claims 8-14 characterized by the above-mentioned. The liquid food is produced according to the following process, and the food and drink according to claim 15;
The extract obtained in claim 8 is crushed in a crusher, and the extract is further crushed in the presence of a polar dilution solvent having a mass of 5 to 20 times that of the crushed extract, and the fine particles of the extract A step of preparing a suspension, and a step of diluting the fine particle suspension obtained above with water. The food / beverage product according to claim 15, which is a liquid beverage produced by the following steps;
(A) Crush the chickpeas and extract with ethanol, filter and separate the extract and chickpea extract residue, repeat the process of extracting the separated chickpea extract residue with ethanol and filtering the extract multiple times Collecting the filtrate and concentrating under pressure at 40 ° C. or lower to obtain an extract;
(B) The extract obtained in (a) was crushed with a crusher, and the crushed extract was further crushed with a crusher in the presence of 5 to 20 times the amount of DMSO aqueous solution to obtain a suspension. Next, the extract in the suspension is microparticulated, and the microparticles are uniformly dispersed in a DMSO aqueous solution to prepare a microparticle suspension; and (c) the microparticle suspension obtained in (b) is water. Thinning process. The food / beverage product according to claim 15, which is a liquid beverage produced by the following steps;
(A) Crush the chickpeas and extract with water, filter and separate the extract and chickpea extract residue, further centrifuge the filtrate to separate the supernatant and chickpea extract residue, filter and Extract the chickpea extract residue obtained by centrifugation with water, filter the extract, centrifuge the filtrate multiple times, collect the supernatant, concentrate under reduced pressure at 60 ° C or lower, extract Obtaining
(B) The extract obtained in (a) was crushed with a crusher, and the crushed extract was further crushed with a crusher in the presence of 5 to 20 times the amount of DMSO aqueous solution to obtain a suspension. Next, the extract in the suspension is microparticulated, and the microparticles are uniformly dispersed in a DMSO aqueous solution to prepare a microparticle suspension; and (c) the microparticle suspension obtained in (b) is water. Thinning process. The food or drink according to any one of claims 8 to 18, which is a food for specified health use.